| pubmed-article:8454440 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0025007 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0042214 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0006684 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0007585 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0042523 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0598312 | lld:lifeskim |
| pubmed-article:8454440 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:8454440 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8454440 | pubmed:dateCreated | 1993-4-21 | lld:pubmed |
| pubmed-article:8454440 | pubmed:abstractText | Kidney cell lines MA104 and BGM were infected with vaccinia and measles viruses respectively in the presence of 45Ca. Increased 45Ca level was detected in the virally infected cells as compared with control cells. An enhancement of 28 +/- 6% and 37 +/- 13% was shown in vaccinia and measles respectively following 5 h of infection. The effect of the calcium antagonist verapamil was studied in both vaccinia- and measles-infected cells. In one-step growth experiments, the mean inhibitory effect of 90 microM verapamil on viral yield after 13 h was 97 +/- 1% in the case of vaccinia. In the measles virus after 47 h a mean of 76 +/- 5% inhibition was detected. The suitability of verapamil as a potential antiviral agent is suggested and requires further investigation. | lld:pubmed |
| pubmed-article:8454440 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8454440 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8454440 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8454440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8454440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8454440 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8454440 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8454440 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8454440 | pubmed:issn | 0021-2180 | lld:pubmed |
| pubmed-article:8454440 | pubmed:author | pubmed-author:ChaimovitzCC | lld:pubmed |
| pubmed-article:8454440 | pubmed:author | pubmed-author:SarovII | lld:pubmed |
| pubmed-article:8454440 | pubmed:author | pubmed-author:Shainkin-Kest... | lld:pubmed |
| pubmed-article:8454440 | pubmed:author | pubmed-author:ZimlichmanSS | lld:pubmed |
| pubmed-article:8454440 | pubmed:author | pubmed-author:WinikoffYY | lld:pubmed |
| pubmed-article:8454440 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8454440 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:8454440 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8454440 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8454440 | pubmed:pagination | 2-6 | lld:pubmed |
| pubmed-article:8454440 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:meshHeading | pubmed-meshheading:8454440-... | lld:pubmed |
| pubmed-article:8454440 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8454440 | pubmed:articleTitle | Inhibitory effect of the calcium antagonist, verapamil, on measles and vaccinia replication in cell culture. | lld:pubmed |
| pubmed-article:8454440 | pubmed:affiliation | Department of Nephrology, Soroka Medical Center, Beer Sheva, Israel. | lld:pubmed |
| pubmed-article:8454440 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8454440 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8454440 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8454440 | lld:pubmed |
